P Coser
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 6
- Multiple Myeloma Research and Treatments 5
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 11
-
- Lymphoma Diagnosis and Treatment 15
- Oncology top 10%
- Viral-associated cancers and disorders 6
- Neurology top 10%
-
- Acute Lymphoblastic Leukemia research 7
-
- Monoclonal and Polyclonal Antibodies Research 4
-
- Lung Cancer Treatments and Mutations 4
In The Last Decade
P Coser
37 papers receiving 875 citations
Peers
Comparison fields: 5 of 58
- Hematology 490
- Genetics 215
- Pathology and Forensic Medicine 324
- Oncology 339
- Neurology 116
Countries citing papers authored by P Coser
This map shows the geographic impact of P Coser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Coser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Coser more than expected).
Fields of papers citing papers by P Coser
This network shows the impact of papers produced by P Coser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Coser. The network helps show where P Coser may publish in the future.
Co-authorship network
The 25 scholars most cited alongside P Coser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 5 | |
| 2 | 2006 | 12 | |
| 3 | 2002 | 1 | |
| 4 | A further case of acute myeloid leukaemia with inv(8)(p11q13) and MOZ-TIF2 fusion. | 2002 | 6 |
| 5 | 2001 | 9 | |
| 6 | 2001 | 2 | |
| 7 | 2001 | 14 | |
| 8 | 2001 | 50 | |
| 9 | 2001 | 19 | |
| 10 | VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. | 2000 | 11 |
| 11 | Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. | 1999 | 13 |
| 12 | 1999 | 26 | |
| 13 | 1999 | 11 | |
| 14 | 1995 | 24 | |
| 15 | 1994 | 31 | |
| 16 | 1991 | 22 | |
| 17 | 1988 | 136 | |
| 18 | 1987 | 9 | |
| 19 | 1985 | 32 | |
| 20 | [Successful pregnancy in acute promyelocytic leukaemia (author's transl)]. | 1979 | 2 |
About P Coser
P Coser is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Internal Medicine and Immunology, having authored 38 papers that have together received 914 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (11 papers), Acute Lymphoblastic Leukemia research (7 papers), Chronic Myeloid Leukemia Treatments (6 papers), Viral-associated cancers and disorders (6 papers), Multiple Myeloma Research and Treatments (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Hematology (490 citations), Genetics (215 citations), Pathology and Forensic Medicine (324 citations), Oncology (339 citations) and Neurology (116 citations). P Coser has collaborated with scholars based in Italy, Germany and Austria. Frequent co-authors include A Congiu, L Mangoni, Angelo Michele Carella, G Broccia, Manfred Mitterer, Giovanna Meloni, Tiziano Barbui, Giuseppe Cimino, Giuseppe Visani and Patrizio Mazza. Their work appears in journals such as Blood, British Journal of Haematology, Annals of Oncology, Acta Haematologica and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.